Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Compugen Ltd. (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CGEN
Nasdaq
8731
http://cgen.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Compugen Ltd. (USA)
12 Best One Dollar Stocks to Buy According To Hedge Funds
- Jan 27th, 2023 2:32 pm
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
- Jan 23rd, 2023 12:00 pm
Why Shares of Compugen Rose on Thursday
- Dec 29th, 2022 9:53 pm
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer
- Dec 6th, 2022 12:00 pm
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients
- Dec 1st, 2022 12:00 pm
Why Shares of Compugen Rose 16.5% on Wednesday
- Nov 30th, 2022 9:49 pm
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
- Nov 29th, 2022 12:00 pm
Why Shares of Compugen Jumped 17.86% on Thursday
- Nov 17th, 2022 9:51 pm
Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific
- Nov 16th, 2022 12:00 pm
Why Compugen Stock Crumbled Today
- Nov 14th, 2022 11:52 pm
Compugen Reports Third Quarter 2022 Results
- Nov 14th, 2022 12:00 pm
Compugen to Participate in the Stifel Healthcare Conference
- Nov 8th, 2022 12:00 pm
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients
- Nov 7th, 2022 1:00 pm
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients
- Nov 7th, 2022 1:00 pm
Compugen Announces Receipt of Nasdaq Delisting Notice
- Nov 2nd, 2022 11:00 am
Why Shares of Compugen Jumped 9.27% on Tuesday
- Nov 1st, 2022 8:41 pm
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022
- Oct 31st, 2022 11:00 am
Compugen to Present New Clinical Data at ESMO-IO
- Oct 26th, 2022 11:00 am
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022
- Oct 6th, 2022 11:00 am
Compugen Letter to Shareholders
- Sep 22nd, 2022 11:00 am
Scroll